Introduction
Tempus AI is a Chicago-based precision medicine company founded in 2015 by Eric Lefkofsky, who continues to serve as its chief executive officer. The company builds technology that organizes clinical, molecular, and imaging data so physicians and researchers can make more informed treatment decisions, particularly in oncology. Tempus has positioned itself not merely as a data repository but as an operating layer where artificial intelligence and multimodal patient records meet day-to-day clinical workflows and pharmaceutical research.
For readers tracking applied AI in healthcare, Tempus is one of the more visible U.S. companies attempting to connect real-world patient data with drug-development pipelines — a problem that sounds straightforward in theory but requires years of data normalization, regulatory care, and institutional trust to execute in practice.
What the company does
Tempus provides a precision medicine platform that ingests and structures clinical and molecular information — including genomic sequencing results, pathology, radiology context, and electronic health record data — then applies analytics and AI models to support treatment decisions, clinical trial matching, and research. Its products are designed to sit inside existing clinical environments rather than replace them, giving oncologists and other specialists structured insights at the point of care while also supplying life-sciences partners with curated datasets for research and development.
The company’s public materials emphasize multimodal data: the argument is that a single lab result or imaging study rarely tells the full story of a complex disease, and that AI becomes materially more useful when it can reason across several validated data types at once.
Who it serves
Tempus sells to health systems and individual clinical practices that need decision support grounded in molecular and clinical data, particularly in cancer care. On the research side, it serves pharmaceutical and biotechnology companies that need access to structured, consented patient datasets to accelerate drug discovery, biomarker identification, and trial design. The Merck collaboration announced in March 2026 reflects this dual customer base: a major pharmaceutical partner working with Tempus on AI-driven precision medicine workflows rather than building equivalent infrastructure entirely in-house.
Company background
Tempus was founded in 2015 in Chicago by Eric Lefkofsky, an entrepreneur who had previously co-founded several technology companies before turning to healthcare data infrastructure. Lefkofsky has remained the public face of Tempus as CEO, and the company has grown from an oncology-focused startup into a broader precision medicine platform with partnerships across health systems and life sciences. In August 2025, Tempus announced the acquisition of Paige, a digital pathology company based in New York, for $81.25 million — a move that extended Tempus’s capabilities in pathology AI, though Brel treats that acquisition primarily as sector context when discussing Tempus rather than as a defining element of this profile.
Product and AI capabilities
Tempus applies machine learning and AI across structured clinical and molecular datasets to surface patterns that would be difficult for manual review alone — from identifying trial-eligible patients to supporting biomarker-driven treatment selection. Its Lens collaboration with Merck, announced March 3, 2026, is described as a multi-year strategic agreement aimed at accelerating AI-driven precision medicine, connecting Tempus’s data and analytics capabilities with Merck’s therapeutic development priorities. The specifics of Lens are framed around making precision medicine workflows faster and more scalable rather than replacing clinician judgment outright.
Tempus’s broader platform strategy assumes that AI models trained on large, curated, multimodal datasets can outperform models built on any single data type — but only if the underlying data pipeline meets clinical and research quality standards. That emphasis on data infrastructure, not just model architecture, distinguishes Tempus from pure algorithm vendors.
Key developments
2015: Tempus founded in Chicago by Eric Lefkofsky. August 22, 2025: Tempus announced the acquisition of Paige for $81.25 million, expanding its digital pathology footprint. March 3, 2026: Tempus announced a multi-year strategic collaboration agreement with Merck to accelerate AI-driven precision medicine through Tempus Lens and related capabilities, per Tempus’s official press release. These developments illustrate a company simultaneously deepening its clinical data platform and extending its pharmaceutical partnership layer.
Why it matters
Tempus matters because it represents one of the more mature attempts to make precision medicine operational at scale — not as a research concept but as software embedded in clinical and pharma workflows. The Merck collaboration is a concrete signal that large pharmaceutical companies are willing to commit to multi-year AI-driven precision medicine partnerships rather than treating clinical AI as experimental tooling. For health system buyers and researchers, Tempus also illustrates how oncology-first platforms can expand into adjacent data modalities when acquisitions such as Paige add complementary capabilities.
Sector context
Tempus belongs in Brel’s AI in healthcare coverage under precision medicine, alongside diagnostic and pathology AI companies such as PathAI and Paige — the latter acquired by Tempus in August 2025. Readers comparing clinical AI vendors may also find it useful to contrast Tempus’s multimodal oncology platform with point-solution companies in cardiology imaging or clinical documentation, where the data types and reimbursement pathways differ materially.
Sources and references
This profile draws on Tempus’s official Merck collaboration press release (March 3, 2026) and the company’s primary website. Acquisition of Paige is cited from Tempus investor communications where referenced in sector context.
- Tempus — Strategic collaboration agreement with Merck (tempus.com, March 3, 2026)
- Tempus — Company website (tempus.com)